-
COVID-19 can trigger self-attacking antibodies
WorldPharmaNews
January 04, 2022
Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all...
-
Treatments in weeks, not months: Scientists develop ambitious pandemic response plan
WorldPharmaNews
January 04, 2022
An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed new and better treatments ...
-
UK life sciences trade group calls for oral Covid-19 antiviral investment
Pharmaceutical-Technology
January 04, 2022
The UK government must invest in Covid-19 antiviral treatments like it did with vaccines, said the chair of the UK BioIndustry Association.
-
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19
Pharmaceutical-Technology
January 04, 2022
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by 89%.
-
Novavax files Covid-19 vaccine data with FDA ahead of EUA application
Pharmaceutical-Technology
January 04, 2022
Novavax has submitted the final data package with the US Food and Drug Administration (FDA) to satisfy the requirements for seeking emergency use authorization (EUA) for its Covid-19 vaccine with Matrix-M adjuvant, NVX-CoV2373.
-
Evotec Receives German Grant for Potential Therapy Against COVID-19
contractpharma
January 04, 2022
Under the grant, Evotec will initiate the clinical development of a potentially highly potent immunomodulatory molecule.
-
MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill
pharmatimes
January 04, 2022
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
-
CDC Backs Boosters for High-Risk Children Ages 5 to 11 Years
drugs
January 04, 2022
The U.S. Centers for Disease Control and Prevention on Tuesday backed the emergency use approval of the Pfizer COVID-19 booster shot for high-risk children between the ages of 5 and 11 years.
-
Israel Will Give Fourth COVID-19 Shot to People Older Than 60, Health Workers
drugs
January 03, 2022
Israel will now offer a fourth dose of COVID-19 vaccine to an expanded group of people, as it works to control a wave of the highly contagious omicron variant.
-
Ascletis expands ritonavir oral tablets production amid Covid-19 surge
pharmaceutical-business-review
January 03, 2022
ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.